THE DEAL, AT A GLANCE
From the announcementAddex spinout Neurosterix
01Who is involvedBacked by Perceptive-affiliated fundsFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedAddex spinout Neurosterix raised $105M Series B, announced 2026-11-12From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersNeurosterix raised a $105M Series B to fund a phase 2 schizophrenia trial, while Addex retains an 8.5% equity interest valued at $18.6 million.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Addex spinout Neurosterix · Financing Record
Explore source-linked visual explanations for Addex spinout Neurosterix. Unsupported claims are withheld while source review continues.
Record 15850 · Recorded date: 2026-11-12
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →